Sign up to save your podcasts
Or
Share Let's Talk Medtech: Why Embecta Stands Out in Diabetes Care
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Let's Talk Medtech: Why Embecta Stands Out in Diabetes Care
Embecta is now fully independent from Becton Dickinson & Co. Devdatt Kurdikar, Embecta's CEO talks about what that means going forward and his plans for the company. With its rich pedigree and newly-independent status, Embecta is truly the new/old kid on the block in diabetes care.
View all episodes
By Informa Markets
4.9
77 ratings
Embecta is now fully independent from Becton Dickinson & Co. Devdatt Kurdikar, Embecta's CEO talks about what that means going forward and his plans for the company. With its rich pedigree and newly-independent status, Embecta is truly the new/old kid on the block in diabetes care.
More shows like Let’s Talk Medtech
View all
WSJ Tech News Briefing
1,646 Listeners
WSJ What’s News
4,338 Listeners
Freakonomics Radio
32,253 Listeners
Goldman Sachs Exchanges
989 Listeners
Hidden Brain
43,367 Listeners
Global Medical Device Podcast powered by Greenlight Guru
91 Listeners
The Daily
111,438 Listeners
Up First from NPR
56,025 Listeners
The Readout Loud
317 Listeners
Med Tech Gurus
17 Listeners
Project Medtech
23 Listeners
SmartLess
57,892 Listeners